Member Info for HelloSanDiego

Woodstock1970 - "Russia is now building troops up on the Polish border."

From what I've read, many Russian troops weren't expecting an invasion and don't support it. If you want an idea of the overall feeling within Putin's close circle, take a look at this video from Monday when he declared the Donbas region independent.

https://www.theguardian.com/world/2022/feb/21/putin-angry-spectacle-amounts-to-declaration-war-ukraine

Thu, 12th Aug 2021 16:12

"The options that have been exercised were due to expire in September 2021. Certain of the new ordinary shares have been sold, at a price of 140p, to meet the tax and subscription costs associated with the exercise, with the remaining shares being retained by the directors."

https://www.lse.co.uk/rns/SNG/exercise-of-options-and-total-voting-rights-p4ay8dt4yb2ns2y.html

Is this "the directors failed and are incompetent" narrative based on the belief that they could and should have ensured that trial patients had the drug (SNG001) without the best available medication (corticosteroids)?

Because I'm not sure they had that option.

Doc83 - "Put in numbers us mere mortals might better comprehend"

I think most people get it. But if you want me to explain it in simpler terms for you, here you go:

If a hedge fund usually makes a 3.6% return in a year, it's foolish to believe 1% isn't a big deal to them. It's not something they can afford to throw away or gamble with.

Doc83 - "£2.5m is actually not that big of a deal for them, when they’re already down say £50m?! "

According to some random Forbes article I found, funds with between $500 million and $1 billion in assets had a weighted average return of 3.36%.

Polygon has invested a further £2.5m when they could have instead recouped around £7.5m. That's £10m they could've reinvested elsewhere. It's also roughly 1% of the fund's value based on its 2014 valuation of £1bn. So, in short, the £10-20m they have invested here is definitely a big deal to them.

Wigster77 - "My post last night probably was a bit OTT"

So was mine, tbh.

The thing is that the point of science is that if it's done properly it should just present the findings. The data is meant to speak for itself, so any attempt to put any kind of spin on it is dubious. Science doesn't really get any more serious than in medicine, so integrity is vital.

Wigster77

That was probably me who said that and I'm sticking with it. Scientists lose credibility the moment they try to put a spin on their results and a communications expert would know that. The only people who think the spin matters would be the ones who could be tricked into being misled by it.

B2HS2L

Replacing the BoD (even partly) and installing a new one with links to a possible buyer would push up the price, I'm sure. That's the last thing a buyer would want to do - inflate the price before buying. So I don't think that seems very likely. I might be wrong though.

Andybe4 - "Pfizer, AZ, Lilly or GSK running their trials with steroids being given to everyone"

Are you talking about the vaccines? That's a different trial. It's not the same as denying hospitalized patients (who might be within days of dying) the best available, approved medicine.

Purple1 - "is there scope to totally change things once results have been analysed carefully"

I don't think there's any chance of that. The trial missed its endpoints and that won't change.

Andybe4 - "This entire fault is because Synairgen are utterly useless and incompetent."

I don't think that's true. Also, Polygon would've been aware of the trial methodology while they were buying at 170p+. So it looks like they don't think it's true either.

If anyone was interested in taking over the company for 212p even with bad results, it would have made sense to build a large position at around 150p in the past six months.

I only know of one company that's done that, and personally I don't seem them risking another £150m here any time soon.

...but as I've said a few times, I think there's hardly any chance of that happening any time soon.

The Panel on Takeovers and Mergers, or more commonly The Takeover Panel, is the regulatory body charged with the administration of The Takeover Code. It was set up in 1968 and is located in London, England.

"When a person or group acquires interests in shares carrying 30% or more of the voting rights of a company, they must make a cash offer to all other shareholders at the highest price paid in the 12 months before the offer was announced..."

https://www.thetakeoverpanel.org.uk/the-code/download-code

Erebus55 - "...company gives an update early next week after Polygon have reviewed the RNS!"

I don't see why Polygon would get to review the next RNS prior to release, but not Monday's one.

TommyD_19 - "It seems clear they’re moving to a percentage position where they have the ability to create or stop any significant decisions company decisions that they’re not happy about.

Don't think so, because they're a long way from that.

25% gives them the ability to stop special resolutions by themselves. But the most important ones (imho) are ordinary resolutions, and they're a long way from being the sole decision makers there. I expect them to stop short of 30% because I think a takeover offer of £1+ is unlikely in the near future. I think they're just betting that we'll get more data and it will be good. That's my opinion though. Could be wrong.

Exactly!

All of us, probably.

Albert

I thought it was the other way round, but your description makes more sense. Either way, it means the strategy for whether to buy, sell or hold that 22.5% is Polygon's decision (and not some amateur investors with barely half a clue between them).

Tradehobbs - "When another holding RNS lands, this will be 40-50p instant."

Doubt it.

Doc83 - "the RNS was garbage. Many respected posters on here have said the same. "

They were reporting the science. It's that simple. "We missed our endpoints. Here's the data".

Anyone who wanted it spun one way or another has no business investing in a drug development company.